argenex (NASDAQ:ARGX) Issues Earnings Results

argenex (NASDAQ:ARGX) announced its quarterly earnings results on Thursday. The company reported $5.52 EPS for the quarter, missing analysts’ consensus estimates of $5.79 by ($0.27), FiscalAI reports. argenex had a return on equity of 33.28% and a net margin of 31.31%.The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.44 billion.

Here are the key takeaways from argenex’s conference call:

• argenx reported strong Q1 results with product net sales of $1.3 billion (63% YoY), an operating profit of $394 million, and a cash balance of $4.9 billion, supporting margin expansion and continued investment in growth.
• Commercial momentum for VYVGART remains strong — Q1 new patient starts were among the highest since launch, the medicine is the #1 prescribed biologic in gMG, the prefilled syringe materially increased demand, and a PDUFA for seronegative MG is imminent with ocular and pediatric expansions planned.
• The company is advancing its second product, empasiprubart, toward a pivotal readout expected in 4Q and argues C2-targeting could offer clinical advantages across CIDP/MMN and other complement-driven indications, positioning a second launch to deepen neuromuscular leadership.
• argenx is broadening its pipeline and sourcing strategy — five clinical-stage molecules (including phase III–ready ARGX?213 and an oral FcRn collaboration), a China entity, and targeted strategic investments to sustain long-term growth and indication expansion.
• Near-term headwinds and risks include seasonal Q1 QoQ softness, rising competition (C5 inhibitors, other newcomers and potential head?to?head trials) largely in refractory settings, payer barriers to earlier-line adoption, and the need for disease awareness to access underdiagnosed populations like IMNM.

argenex Stock Down 0.7%

ARGX traded down $5.14 during trading on Friday, hitting $782.17. The company’s stock had a trading volume of 354,205 shares, compared to its average volume of 307,650. The stock has a market capitalization of $48.64 billion, a price-to-earnings ratio of 35.05, a price-to-earnings-growth ratio of 1.29 and a beta of 0.46. The firm’s 50 day moving average price is $755.88 and its two-hundred day moving average price is $817.54. argenex has a 12 month low of $510.05 and a 12 month high of $934.62.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Truist Financial increased their price objective on argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Wells Fargo & Company boosted their target price on shares of argenex from $1,247.00 to $1,260.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Guggenheim upped their target price on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,017.78.

Institutional Trading of argenex

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Rafferty Asset Management LLC bought a new stake in argenex during the 4th quarter worth about $343,000. Dorsey & Whitney Trust CO LLC lifted its position in shares of argenex by 10.8% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 391 shares of the company’s stock worth $328,000 after purchasing an additional 38 shares in the last quarter. Index Technologies Group LLC bought a new stake in shares of argenex during the fourth quarter valued at approximately $301,000. AQR Capital Management LLC grew its stake in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares during the last quarter. Finally, Merit Financial Group LLC acquired a new stake in shares of argenex in the third quarter valued at approximately $266,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Guggenheim raised its price target on argenx to $1,135 and kept a buy rating, implying substantial upside from current levels. Guggenheim Raises ARGX Price Target
• Positive Sentiment: Wells Fargo also increased its price target to $1,260 and reiterated an overweight rating, signaling continued confidence in argenx’s long-term growth prospects. Wells Fargo Raises ARGX Price Target
• Neutral Sentiment: argenx reported Q1 2026 results and a business update, with investors parsing the details of the quarter and management’s outlook. argenx Q1 2026 Financial Results and Business Update
• Negative Sentiment: The company posted earnings of $5.52 per share, below the $5.79 consensus estimate, and revenue of $1.31 billion also missed expectations, which is likely weighing on the stock. Argenx Tops Earnings Expectations Despite Slight Revenue Shortfall

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.